Browse MSR1

Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type II membrane protein.
Domain PF01391 Collagen triple helix repeat (20 copies)
PF03523 Macrophage scavenger receptor
PF00530 Scavenger receptor cysteine-rich domain
Function

Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL) (PubMed:2251254). Isoform III does not internalize acetylated LDL (PubMed:9548586).

> Gene Ontology
 
Biological Process GO:0006869 lipid transport
GO:0006898 receptor-mediated endocytosis
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010744 positive regulation of macrophage derived foam cell differentiation
GO:0010876 lipid localization
GO:0010878 cholesterol storage
GO:0010883 regulation of lipid storage
GO:0010884 positive regulation of lipid storage
GO:0010885 regulation of cholesterol storage
GO:0010886 positive regulation of cholesterol storage
GO:0015850 organic hydroxy compound transport
GO:0015918 sterol transport
GO:0019915 lipid storage
GO:0030301 cholesterol transport
GO:0034381 plasma lipoprotein particle clearance
GO:0042953 lipoprotein transport
GO:0044872 lipoprotein localization
GO:0051235 maintenance of location
GO:0071407 cellular response to organic cyclic compound
GO:0090077 foam cell differentiation
GO:0097006 regulation of plasma lipoprotein particle levels
Molecular Function GO:0005044 scavenger receptor activity
GO:0030169 low-density lipoprotein particle binding
GO:0038024 cargo receptor activity
GO:0071813 lipoprotein particle binding
GO:0071814 protein-lipid complex binding
Cellular Component GO:0005581 collagen trimer
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:0034362 low-density lipoprotein particle
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-3000480: Scavenging by Class A Receptors
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MSR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MSR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21383767Pancreatic CarcinomaInhibit immunityAbsence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response. Selective downregulation or blockade of this immunoregulatory molecule may lead to enhanced potency of DC-based vaccines capable of breaking immune tolerance against cancer.
22896667Prostate CarcinomaInhibit immunityIn situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. SRA/CD204-silenced DCs were highly efficient in generating antigen or tumor-specific T cells with increased effector functions (e.g., cytokine production and tumoricidal activity). SRA/CD204 silencing-enhanced tumor cell death was associated with elevated IFN-γ levels in tumor tissue and increased tumor-infiltrating CD8(+) cells.
17510431MelanomaInhibit immunity; Resistant to immunotherapyScavenger receptor-A negatively regulates antitumor immunity. The lack of SR-A significantly enhances HSP- or lipopolysaccharide-mediated vaccine activities against poorly immunogenic tumors, indicating that SR-A is able to attenuate immunostimulatory effects of adjuvants or "danger" molecules. The improved antitumor response in SR-A knockout mice is correlated with an increased antigen-specific T-cell response. Moreover, SR-A-deficient dendritic cells are more responsive to inflammatory stimuli and display a more effective antigen-presenting capability compared with wild-type cells.
21914786MelanomaInhibit immunityOur studies establish that downregulating SRA/CD204 strongly enhances DC-mediated antitumor immunity. Using SRA/CD204-silenced DCs to generate antigen-targeted vaccines, we documented a marked increase in the level of antitumor immunity achieved against established B16 tumors and metastases.
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MSR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5970.274
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8310.673
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4180.759
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2990.506
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5030.79
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.040.987
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2310.667
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2670.883
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.190.925
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8650.583
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1950.65
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0370.85
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.48.2-0.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MSR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MSR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MSR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MSR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MSR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MSR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMSR1
Namemacrophage scavenger receptor 1
Aliases SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location8p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MSR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.